Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home
Share
Compartir

CDC's Response to Ending Neglect

Return to CDC's Response Main Menu

The documents listed below are historical, archived information. The information contained in these documents, while accurate at the time of release, may not be the most current available.

References

  1. CDC. 1989. A strategic plan for the elimination of tuberculosis in the United States. MMWR 1989;38 (Suppl S-3).
  2. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 55: 1595-1600.
  3. Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 72: 535-39.
  4. CDC. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons Florida and New York, 1988-1991. MMWR 1991; 40: 585-91.
  5. CDC. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992; 41 (RR-11).
  6. CDC. Reported Tuberculosis in the United States, 2000. Atlanta, GA: DHHS/CDC; August 2001.
  7. CDC. Reported Tuberculosis in the United States, 2001. Atlanta, GA: DHHS/CDC; 2001. Available http://www.cdc.gov/tb/surv/default.htm. Accessed July 2002.
  8. Miller B, Castro KG. Sharpen available tools for tuberculosis control, but new tools needed for elimination. JAMA 1996; 276: 1916-17.
  9. Talbot EA, Moore M, McCray E, Binkin NJ. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA 2000; 284: 2894-2900.
  10. Goldberg BW. Managed care and public health departments: who is responsible for the health of the population? Annu Rev Public Health 1998; 19: 527-37.
  11. Institute of Medicine. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
  12. Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996; 334: 933-938.
  13. Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995; 333 (4): 222-227.
  14. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City turning the tide. N Engl J Med 1995; 333 (4): 229-33.
  15. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-16.
  16. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 33: 1703-9.
  17. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1229-30.
  18. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943-8.
  19. McKenna MT, McCray E, Jones JL, Onorato IM, Castro KG. The fall after the rise: tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998; 88: 1059-63.
  20. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999; 3: 272-80.
  21. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2017-18.
  22. Reichler M, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287(8): 991-995.
  23. Halverson PK, Mays GP, Miler CA, Daluzny AD, Richards TB. Managed care and the public health challenge of TB. Public Health Reports 1997; 112: 22-8.
  24. Miller B, Rosenbaum S, Strange PV, Solomon SL, Castro KG. Tuberculosis control in a changing health care system: model contract specifications for managed care organizations. Clin Infect Dis 1998; 27: 677-86.
  25. Rutherford GW. Public health, communicable diseases, and managed care: will managed care improve or weaken communicable disease control? Am J Prev Med 1998; 14 (Suppl): 53-9.
  26. Crawford JT. New technologies in the diagnosis of tuberculosis. Semin Respir Infect 1994; 9: 62-70.
  27. American Thoracic Society (ATS). Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997; 155(5): 1804-14.
  28. World Health Organization. Framework for Effective Tuberculosis Control. Geneva: WHO; 1994.
  29. Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis a molecular story. J Med Microbiol 1998; 47: 189-96.
  30. Lyashchenko K, Colangeli R, Houde M. Al Jahdali H, Menzies D, Gennaro ML. Heterogeneous antibody responses in tuberculosis. Infect Immun 1998; 66: 3936-40.
  31. Samanich KM, Belisle JT, Sonnenberg MG, Keen MA, Zolla-Pazner S, Laal SJ. Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. Infect Dis 1998; 178: 1534-8.
  32. Streeton JA, Desem N, Jones SL. 1998. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998; 2: 443-50.
  33. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
  34. Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 1997; 25: 806-10.
  35. Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56: 607-16.
  36. CDC. Notice to readers: Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998; 47: 911-12.
  37. O'Brien RJ, Vernon AA. New tuberculosis drug development. How can we do it better? Am J Respir Crit Care Med 1998; 157: 1705-7.
  38. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
  39. Ginsberg AM. A proposed national strategy for tuberculosis vaccine development. Clin Infect Dis 2000; 30 (Suppl 3): S233-S242.
  40. World Health Organization. The World Health Report: Making a Difference. Geneva: WHO; 1999: 116.
  41. Zuber PLF, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278: 304-7.
  42. Netto EM, Dye C, Raviglione MC. Progress in global TB control 1995-96, with emphasis on 22 high-incidence countries. Int J Tuberc Lung Dis 1999; 3(4): 310-320.
  43. Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis 1996; 77: 220-5.
  44. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization - Interrnational Union Against Tuberculosis and Lung Disease Working Group on Antituberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
  45. CDC. Tuberculosis morbidity United States, 1997. MMWR 1998; 47: 253-57.
  46. Cantwell MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998; 157: 1016-20.
  47. Binkin NJ, Vernon AA, Simone PM, et al. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. Int J Tuberc Lung Dis 1999; 3: 663-74.
  48. CDC. Tuberculosis control laws United States, 1993: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1993; 42 (RR-15).
  49. American Thoracic Society (ATS)/CDC. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-95.
  50. Chaulk CP, Grady M. Evaluating tuberculosis control programs: strategies, tools and models. Int J Tuberc Lung Dis 2000; 4 (Suppl): S55-S60.
  51. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997; 12: 63-70.
  52. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-5.
  53. Snider DE, Cauthen GM, Farer LS, et al. Drug-resistant tuberculosis. Am Rev Respir Dis 1991; 144: 732.
  54. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-671.
  55. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-837.
  56. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities, 1994. MMWR 1994; 43 (RR-13).
  57. CDC. Instructions to Panel Physicians for Completing Chest X-Ray and Classification Worksheet. Available at http://www.cdc.gov/ncidod/dq/dsforms/3024.htm. Accessed August 2002.
  58. CDC. Essential components of a tuberculosis prevention and control program: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1995; 44 (RR-11): 1-16.
  59. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-75.
  60. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities and next steps. Am J Respir Crit Care Med 2001; 163: 1055-1058.
  61. Datta M, Radhamani MP, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber Lung Dis 1993; 74: 180-6.
  62. CDC. Primary multidrug-resistant tuberculosis Ivanovo Oblast, Russia, 1999. MMWR 1999; 48: 661-3.
  63. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-91.
  64. World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiol Rec 1999; 74: 385-98.
  65. CDC. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1998; 47 (RR-13): 1-6.
  66. CDC. Improving Tuberculosis Treatment and Control: An Agenda for Behavioral, Social, and Health Systems Research. Proceedings of Tuberculosis and Behavior: National Workshop on Research for the 21st Century; August 28-30, 1994, Bethesda, MD. Atlanta, GA: CDC;1995.
  67. DHHS. Making health communications programs work: planning guide. Washington, DC: DHHS; 1992.
 
Contact Us:
  • Centers for Disease Control and Prevention
    Division of Tuberculosis Elimination (DTBE)
    1600 Clifton Rd., NE
    MS E10
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #